Compare Stocks: ALLR, OKYO, PLRX, and APLM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.03	$1.29	$0.77 ▼ $1.84	$16.39M	0.56	111,954 shs	43,322 shs
APLM Apollomics	$22.35	$22.05	$10.01 ▼ $42.12	$65.04M	1.53	10,930 shs	39,570 shs
OKYO OKYO Pharma	$1.38	$1.50	$1.28 ▼ $3.20	$72.42M	0.03	82,183 shs	87,733 shs
PLRX Pliant Therapeutics	$1.08	$1.11	$1.02 ▼ $1.95	$66.87M	1.27	394,593 shs	450,184 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-14.88%	-26.95%	-20.77%	-34.81%
APLM Apollomics	0.00%	-1.13%	-15.98%	+5.23%	+21.25%
OKYO OKYO Pharma	0.00%	+1.47%	-17.37%	-9.21%	-36.70%
PLRX Pliant Therapeutics	0.00%	-2.70%	-2.70%	-6.09%	-28.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.03	$1.29	$0.77 ▼ $1.84	$16.39M	0.56	111,954 shs	43,322 shs
APLM Apollomics	$22.35	$22.05	$10.01 ▼ $42.12	$65.04M	1.53	10,930 shs	39,570 shs
OKYO OKYO Pharma	$1.38	$1.50	$1.28 ▼ $3.20	$72.42M	0.03	82,183 shs	87,733 shs
PLRX Pliant Therapeutics	$1.08	$1.11	$1.02 ▼ $1.95	$66.87M	1.27	394,593 shs	450,184 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-14.88%	-26.95%	-20.77%	-34.81%
APLM Apollomics	0.00%	-1.13%	-15.98%	+5.23%	+21.25%
OKYO OKYO Pharma	0.00%	+1.47%	-17.37%	-9.21%	-36.70%
PLRX Pliant Therapeutics	0.00%	-2.70%	-2.70%	-6.09%	-28.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	895.15% Upside
APLM Apollomics	1.00	Sell	N/A	N/A
OKYO OKYO Pharma	2.50	Moderate Buy	$5.67	310.63% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	177.78% Upside

Current Analyst Ratings Breakdown

Latest ALLR, OKYO, PLRX, and APLM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	OKYO OKYO Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	51.21	N/A	N/A	$0.61 per share	1.69
APLM Apollomics	$8.50M	7.65	N/A	N/A	($2.89) per share	-7.73
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A
PLRX Pliant Therapeutics	$1.58M	42.33	N/A	N/A	$2.95 per share	0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)

Latest ALLR, OKYO, PLRX, and APLM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
APLM Apollomics	N/A	0.96	0.96
OKYO OKYO Pharma	N/A	2.43	2.43
PLRX Pliant Therapeutics	N/A	9.90	9.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
APLM Apollomics	19.13%
OKYO OKYO Pharma	2.97%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
APLM Apollomics	N/A
OKYO OKYO Pharma	40.46%
PLRX Pliant Therapeutics	8.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	8	15.91 million	15.89 million	Not Optionable
APLM Apollomics	15	2.91 million	N/A	Not Optionable
OKYO OKYO Pharma	5	52.48 million	31.25 million	Not Optionable
PLRX Pliant Therapeutics	49	61.92 million	56.51 million	Optionable

ALLR, OKYO, PLRX, and APLM Headlines

Recent News About These Companies

Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen

September 26 at 1:24 AM | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Raised to Hold at Wall Street Zen

September 26 at 1:23 AM | marketbeat.com

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $3.00 Average Target Price from Analysts

September 17, 2026 | americanbankingnews.com

Pliant Therapeutics consensus price target lowered 20% to $2.04

September 16, 2026 | msn.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of "Reduce" by Brokerages

September 12, 2026 | marketbeat.com

BlackRock Inc. Makes New $1.31 Million Investment in Pliant Therapeutics, Inc. $PLRX

September 7, 2026 | marketbeat.com

Pliant Therapeutics Inc Ordinary Shares PLRX

August 28, 2026 | morningstar.comM

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/08/18/3346838/0/en/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-101095-in-combination-with-pembrolizumab-for-the-treatment-of-ici-refractory-solid-tumors.html$

Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

August 14, 2026 | theglobeandmail.com

Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 12, 2026 | finanznachrichten.de

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026 | globenewswire.com

Pliant Therapeutics adds independent directors to strengthen R&D

July 13, 2026 | tipranks.com

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

July 13, 2026 | globenewswire.com

Pliant Therapeutics Shareholders Approve Directors and Executive Pay

June 11, 2026 | tipranks.com

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 22, 2026 | seekingalpha.com

Pliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026

May 21, 2026 | quiverquant.comQ

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026 | globenewswire.com

Pliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | Benzinga

May 17, 2026 | benzinga.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026 | finance.yahoo.com

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, OKYO, PLRX, and APLM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.03 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.05 +0.02 (+1.84%)

As of 09/25/2026 07:02 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Apollomics NASDAQ:APLM

$22.35 0.00 (0.00%)

Closing price 09/25/2026 03:56 PM Eastern

Extended Trading

$22.32 -0.04 (-0.16%)

As of 09/25/2026 07:30 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

OKYO Pharma NASDAQ:OKYO

$1.38 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 09/25/2026 07:30 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Pliant Therapeutics NASDAQ:PLRX

$1.08 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.08 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, OKYO, PLRX, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, OKYO, PLRX, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, OKYO, PLRX, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, OKYO, PLRX, and APLM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Apollomics NASDAQ:APLM

OKYO Pharma NASDAQ:OKYO

Pliant Therapeutics NASDAQ:PLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, OKYO, PLRX, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, OKYO, PLRX, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, OKYO, PLRX, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, OKYO, PLRX, and APLM Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Apollomics NASDAQ:APLM

OKYO Pharma NASDAQ:OKYO

Pliant Therapeutics NASDAQ:PLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools